名古屋大学大学院医学系研究科 脳神経外科
脳神経外科HOME >> 脳神経外科のご紹介 >>臨床研究グループ >> 脳腫瘍グループ

脳腫瘍グループ


1.グループ紹介

 脳腫瘍グループは、良性脳腫瘍から悪性脳腫瘍にいたるすべての頭蓋内腫瘍を対象として、正確な診断と最高レベルの治療の提供に努め、更により良い医療を目指して研究に取り組んでいる。臨床面では、術中MRI を用いた正確で高度な画像誘導手術・覚醒下開頭術・電気生理学的モニタリング技術等を駆使して世界最先端の脳腫瘍手術を実践する他、これまでの豊富な治療経験と最新の知見を取り入れた「名大方式悪性脳腫瘍治療指針」を作成して、放射線・化学療法等補助療法を含めた集学的治療を行っている。研究面では、脳腫瘍の病態解明と新たな治療開発を行うための基礎研究を展開するとともに、これらの研究成果をもとに、遺伝子再生医療センターを活用して、実際の臨床応用を目指した橋渡し臨床研究を実施している。また、生物学的アプローチのみならず、コンピュータサイエンスを取り入れた手術支援技術の改良・開発研究にも取り組んでいる。名古屋大学内を含め国内外と共同した学際的研究・多施設共同臨床研究を積極的に押し進めていることも大きな特徴である。

2.スタッフ

夏目 敦至 Atsushi NATSUME (平成7年卒: 准教授)
本村 和也 Kazuya MOTOMURA (平成14年卒: 特任准教授)
大岡 史治 Fumiharu Ohka (平成16年卒: 病院助教)
近藤 五郎 Goro KONDOU (平成19年卒: 特任助教)
     
倉光 俊一郎 Shunichiro KURAMITSU (平成17年卒: 大学院生)
山本 高士 Takashi YAMAMOTO (平成19年卒: 大学院生)
飯島 健太郎 Kentaro IIJIMA (平成20年卒: 大学院生)
栗本 路弘 Michihiro KURIMOTO (平成20年卒: 大学院生)
出口 彰一 Shouichi DEGUCHI (平成20年卒: 大学院生)
平野 雅規 Masaki HIRANO (平成21年卒: 大学院生)
Chalise Lushun   (平成21年卒: 大学院生)
Melissa Ranjit   (2006年卒: Tribhuvan University: 大学院生)
     
その他    
鈴木 啓道 Hiromichi SUZUKI (平成17年卒: 京都大学医学研究科腫瘍生物学講座・
研究員)
辻内 高士 Takashi TSUJIUCHI (平成17年卒: Columbia University, NY, USA留学)
青木 恒介 Kosuke AOKI (平成18年卒: 大学院生)

3.論文業績

Recent Publications (English peer-reviewed articles only 2010〜)

  1. Motomura K, Fujii M, Maesawa S, Kuramitsu S, Natsume A, Wakabayashi T. Association of dorsal inferior frontooccipital fasciculus fibers in the deep parietal lobe with both reading and writing processes: a brain mapping study. Journal of neurosurgery. 2014. doi:10.3171/2014.2.JNS131234.
  2. Ohka F, Ito M, Ranjit M, Senga T, Motomura A, Motomura K, Saito K, Kato K, Kato Y, Wakabayashi T, Soga T, Natsume A. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014. doi:10.1007/s13277-014-1784-5.
  3. Umebayashi D, Natsume A, Takeuchi H, Hara M, Nishimura Y, Fukuyama R, Sumiyoshi N, Wakabayashi T. Blockade of gap junction hemichannel protects secondary spinal cord injury from activated microglia-mediated glutamate exito-neurotoxicity. Journal of neurotrauma. 2014. doi:10.1089/neu.2013.3223.
  4. Tsujiuchi T, Natsume A, Motomura K, Kondo G, Ranjit M, Hachisu R, Sugimura I, Tomita S, Takehara I, Woolley M, Barua NU, Gill SS, Bienemann AS, Yamashita Y, Toyokuni S, Wakabayashi T. Preclinical evaluation of an O(6)-methylguanine-DNA methyltransferase-siRNA/liposome complex administered by convection-enhanced delivery to rat and porcine brains. Am J Transl Res. 2014;6(2):169-78.
  5. Yamashita Y, Ito Y, Isomura H, Takemura N, Okamoto A, Motomura K, Tsujiuchi T, Natsume A, Wakabayashi T, Toyokuni S, Tsurumi T. Lack of presence of the human cytomegalovirus in human glioblastoma. Mod Pathol. 2013. doi:10.1038/modpathol.2013.219.
  6. Ando H, Natsume A, Senga T, Watanabe R, Ito I, Ohno M, Iwami K, Ohka F, Motomura K, Kinjo S, Ito M, Saito K, Morgan R, Wakabayashi T. Peptide-based inhibition of the HOXA9/PBX interaction retards the growth of human meningioma. Cancer chemotherapy and pharmacology. 2014;73(1):53-60. doi:10.1007/s00280-013-2316-5.
  7. Hasegawa H, Hyodo T, Asano E, Ito S, Maeda M, Kuribayashi H, Natsume A, Wakabayashi T, Hamaguchi M, Senga T. The role of PLK1-phosphorylated SVIL in myosin II activation and cytokinetic furrowing. J Cell Sci. 2013;126(Pt 16):3627-37. doi:10.1242/jcs.124818.
  8. Natsume A, Ito M, Katsushima K, Ohka F, Hatanaka A, Shinjo K, Sato S, Takahashi S, Ishikawa Y, Takeuchi I, Shimogawa H, Uesugi M, Okano H, Kim SU, Wakabayashi T, Issa JP, Sekido Y, Kondo Y. Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma. Cancer research. 2013;73(14):4559-70. doi:10.1158/0008-5472.CAN-13-0109.
  9. Kato Y, Natsume A, Kaneko MK. A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation. Biochemical and biophysical research communications. 2013;432(4):564-7. doi:10.1016/j.bbrc.2013.02.049.
  10. Ando H, Natsume A, Iwami K, Ohka F, Kuchimaru T, Kizaka-Kondoh S, Ito K, Saito K, Sugita S, Hoshino T, Wakabayashi T. A hypoxia-inducible factor (HIF)-3alpha splicing variant, HIF-3alpha4 impairs angiogenesis in hypervascular malignant meningiomas with epigenetically silenced HIF-3alpha4. Biochemical and biophysical research communications. 2013;433(1):139-44. doi:10.1016/j.bbrc.2013.02.044.
  11. Iwami K, Natsume A, Ohno M, Ikeda H, Mineno J, Nukaya I, Okamoto S, Fujiwara H, Yasukawa M, Shiku H, Wakabayashi T. Adoptive transfer of genetically modified Wilms' tumor 1-specific T cells in a novel malignant skull base meningioma model. Neuro-oncology. 2013;15(6):747-58. doi:10.1093/neuonc/not007.
  12. Kaneko MK, Morita S, Tsujimoto Y, Yanagiya R, Nasu K, Sasaki H, Hozumi Y, Goto K, Natsume A, Watanabe M, Kumabe T, Takano S, Kato Y. Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations. Biochemical and biophysical research communications. 2013;432(1):40-5. doi:10.1016/j.bbrc.2013.01.088.
  13. Kanno H, Kuratsu J, Nishikawa R, Mishima K, Natsume A, Wakabayashi T, Houkin K, Terasaka S, Shuin T. Clinical features of patients bearing central nervous system hemangioblastoma in von Hippel-Lindau disease. Acta Neurochir (Wien). 2013;155(1):1-7. doi:10.1007/s00701-012-1514-y.
  14. Nishimura Y, Natsume A, Ito M, Hara M, Motomura K, Fukuyama R, Sumiyoshi N, Aoki I, Saga T, Lee HJ, Wakabayashi T, Kim SU. Interferon-beta delivery via human neural stem cell abates glial scar formation in spinal cord injury. Cell Transplant. 2013;22(12):2187-201. doi:10.3727/096368912X657882.
  15. Wang C, Natsume A, Lee HJ, Motomura K, Nishimira Y, Ohno M, Ito M, Kinjo S, Momota H, Iwami K, Ohka F, Wakabayashi T, Kim SU. Neural stem cell-based dual suicide gene delivery for metastatic brain tumors. Cancer gene therapy. 2012;19(11):796-801. doi:10.1038/cgt.2012.63.
  16. Motomura K, Natsume A, Watanabe R, Ito I, Kato Y, Momota H, Nishikawa R, Mishima K, Nakasu Y, Abe T, Namba H, Nakazato Y, Tashiro H, Takeuchi I, Mori T, Wakabayashi T. Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas. Cancer science. 2012;103(10):1871-9. doi:10.1111/j.1349-7006.2012.02377.x.
  17. Katsushima K, Shinjo K, Natsume A, Ohka F, Fujii M, Osada H, Sekido Y, Kondo Y. Contribution of microRNA-1275 to Claudin11 protein suppression via a polycomb-mediated silencing mechanism in human glioma stem-like cells. The Journal of biological chemistry. 2012;287(33):27396-406. doi:10.1074/jbc.M112.359109.
  18. Ohno M, Natsume A, Wakabayashi T. Cytokine therapy. Adv Exp Med Biol. 2012;746:86-94. doi:10.1007/978-1-4614-3146-6_7.
  19. Ohka F, Natsume A, Wakabayashi T. Current trends in targeted therapies for glioblastoma multiforme. Neurol Res Int. 2012;2012:878425. doi:10.1155/2012/878425.
  20. Iwami K, Shimato S, Ohno M, Okada H, Nakahara N, Sato Y, Yoshida J, Suzuki S, Nishikawa H, Shiku H, Natsume A, Wakabayashi T. Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor alpha2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy. 2012;14(6):733-42. doi:10.3109/14653249.2012.666633.
  21. Kishida Y, Natsume A, Toda H, Toi Y, Motomura K, Koyama H, Matsuda K, Nakayama O, Sato M, Suzuki M, Kondo Y, Wakabayashi T. Correlation between quantified promoter methylation and enzymatic activity of O6-methylguanine-DNA methyltransferase in glioblastomas. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2012;33(2):373-81. doi:10.1007/s13277-012-0319-1.
  22. Iwami K, Momota H, Natsume A, Kinjo S, Nagatani T, Wakabayashi T. A novel method of intracranial injection via the postglenoid foramen for brain tumor mouse models. Journal of neurosurgery. 2012;116(3):630-5. doi:10.3171/2011.10.JNS11852.
  23. Kishida Y, Natsume A, Kondo Y, Takeuchi I, An B, Okamoto Y, Shinjo K, Saito K, Ando H, Ohka F, Sekido Y, Wakabayashi T. Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses. Carcinogenesis. 2012;33(2):436-41. doi:10.1093/carcin/bgr260.
  24. Natsume A, Kato T, Kinjo S, Enomoto A, Toda H, Shimato S, Ohka F, Motomura K, Kondo Y, Miyata T, Takahashi M, Wakabayashi T. Girdin maintains the stemness of glioblastoma stem cells. Oncogene. 2012;31(22):2715-24. doi:10.1038/onc.2011.466.
  25. Ohka F, Natsume A, Motomura K, Kishida Y, Kondo Y, Abe T, Nakasu Y, Namba H, Wakai K, Fukui T, Momota H, Iwami K, Kinjo S, Ito M, Fujii M, Wakabayashi T. The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. PLoS One. 2011;6(8):e23332. doi:10.1371/journal.pone.0023332.
  26. Motomura K, Natsume A, Fujii M, Ito M, Momota H, Wakabayashi T. Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy. Leukemia & lymphoma. 2011;52(11):2069-75. doi:10.3109/10428194.2011.596967.
  27. Motomura K, Natsume A, Wakabayashi T. Intravenous administration of temozolomide as a useful alternative over oral treatment with temozolomide capsules in patients with gliomas. Journal of neuro-oncology. 2012;106(1):209-11. doi:10.1007/s11060-011-0651-0.
  28. Iwami K, Natsume A, Wakabayashi T. Cytokine networks in glioma. Neurosurgical review. 2011;34(3):253-63; discussion 63-4. doi:10.1007/s10143-011-0320-y.
  29. Motomura K, Natsume A, Kishida Y, Higashi H, Kondo Y, Nakasu Y, Abe T, Namba H, Wakai K, Wakabayashi T. Benefits of interferon-beta and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study. Cancer. 2011;117(8):1721-30. doi:10.1002/cncr.25637.
  30. Wakabayashi T, Kayama T, Nishikawa R, Takahashi H, Hashimoto N, Takahashi J, Aoki T, Sugiyama K, Ogura M, Natsume A, Yoshida J. A multicenter phase I trial of combination therapy with interferon-beta and temozolomide for high-grade gliomas (INTEGRA study): the final report. Journal of neuro-oncology. 2011;104(2):573-7. doi:10.1007/s11060-011-0529-1.
  31. Natsume A, Kinjo S, Yuki K, Kato T, Ohno M, Motomura K, Iwami K, Wakabayashi T. Glioma-initiating cells and molecular pathology: implications for therapy. Brain tumor pathology. 2011;28(1):1-12. doi:10.1007/s10014-010-0011-3.
  32. Momota H, Iwami K, Fujii M, Motomura K, Natsume A, Ogino J, Hasegawa T, Wakabayashi T. Rhabdoid glioblastoma in a child: case report and literature review. Brain tumor pathology. 2011;28(1):65-70. doi:10.1007/s10014-010-0010-4.
  33. Natsume A, Motomura K, Wakabayashi T. [The genome atlas of brain tumors]. Nihon rinsho Japanese journal of clinical medicine. 2010;68 Suppl 8:473-80.
  34. Iwami K, Natsume A, Wakabayashi T. Gene therapy for high-grade glioma. Neurologia medico-chirurgica. 2010;50(9):727-36.
  35. Ohno M, Natsume A, Ichiro Iwami K, Iwamizu H, Noritake K, Ito D, Toi Y, Ito M, Motomura K, Yoshida J, Yoshikawa K, Wakabayashi T. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen. Cancer science. 2010;101(12):2518-24. doi:10.1111/j.1349-7006.2010.01734.x.
  36. Motomura K, Ogura M, Natsume A, Yokoyama H, Wakabayashi T. A free-radical scavenger protects the neural progenitor cells in the dentate subgranular zone of the hippocampus from cell death after X-irradiation. Neuroscience letters. 2010;485(1):65-70. doi:10.1016/j.neulet.2010.08.065.
  37. Kato T, Natsume A, Toda H, Iwamizu H, Sugita T, Hachisu R, Watanabe R, Yuki K, Motomura K, Bankiewicz K, Wakabayashi T. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Gene therapy. 2010;17(11):1363-71. doi:10.1038/gt.2010.88.
  38. Natsume A, Kondo Y, Ito M, Motomura K, Wakabayashi T, Yoshida J. Epigenetic aberrations and therapeutic implications in gliomas. Cancer science. 2010;101(6):1331-6. doi:10.1111/j.1349-7006.2010.01545.x.
  39. Ito S, Natsume A, Shimato S, Ohno M, Kato T, Chansakul P, Wakabayashi T, Kim SU. Human neural stem cells transduced with IFN-beta and cytosine deaminase genes intensify bystander effect in experimental glioma. Cancer gene therapy. 2010;17(5):299-306. doi:10.1038/cgt.2009.80.

↑このページの先頭へ